BioCryst Pharmaceuticals Profile

USD 0.06  1.14%

Exercise or conversion by Bennett J Claude of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3

BioCryst Pharmaceuticals Inc insider trading alert for exercise of stock option by Bennett J Claude, President, on March 14, 2018. This event was filed by Biocryst Pharmaceuticals with SEC on 2006-03-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

BioCryst Pharmaceuticals Summary

BioCryst Pharmaceuticals Inc (BCRX) is traded on NASDAQ in USA. It is located in NORTH CAROLINA, U.S.A and employs 85 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 496.97 M. BioCryst Pharmaceuticals Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 98.61 M outstanding shares of which 10.82 M shares are currently shorted by private and institutional investors with about 10.04 trading days to cover. BIOCRYST PHARM IN currently holds about 114.4 M in cash with (41.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.16.
Check BioCryst Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Baker Bros Advisors LpCommon Shares14 M68.7 M
Blackrock IncCommon Shares7.6 M37.4 M
View BioCryst Pharmaceuticals Diagnostics

Selected BioCryst Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

BioCryst Pharmaceuticals Against Markets

Current Ratings

BioCryst Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 58% 
Equity ratings for BioCryst Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. BioCryst Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 85 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameBioCryst Pharmaceuticals Inc
CEOJon StonehouseView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address4505 Emperor Boulevard
CIK Number00882796.0
IndustryPharmaceutical Products
Contact Number919 859 1302
CurrencyUSD - US Dollar

Current Sentiment - BCRX

BioCryst Pharmaceuticals Investor Sentiment
Most of Macroaxis users are currently bullish on BioCryst Pharmaceuticals Inc. What is your opinion about investing in BioCryst Pharmaceuticals Inc? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide


BioCryst Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
BioCryst Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
BioCryst Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


BioCryst Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.25February 27, 2017
BioCryst Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


BioCryst Pharmaceuticals Corporate Directors
Fred Cohen Director, Ph.D
Stanley Erck Independent Director
Robert Ingram Director